OVS (OVS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 Nov, 2025Executive summary
Net sales for Q1 2025 reached €354.4 million, up 0.6–1% year-over-year, with strong performance in womenswear and beauty segments despite macroeconomic headwinds and adverse weather.
EBITDA for Q1 2025 was €28.1 million, down €1.5–1.6 million from Q1 2024, mainly due to inflationary overhead and fixed SG&A costs.
Profit before tax stood at €8.0 million, with stable depreciation and financial expenses.
The accelerated acquisition of 100% of Goldenpoint aims to boost synergies and profitability in the underwear segment, with integration and relaunch underway.
Strong start to Q2 with mid-single-digit sales growth expected, supporting confidence in full-year growth.
Financial highlights
Net sales: €354.4 million (+0.6% vs. Q1 2024); EBITDA: €28.1 million (-5.3% year-over-year); EBIT: €12.4 million.
EBITDA margin at 7.9% (vs. 8.4% in Q1 2024); EBIT margin at 3.5% (vs. 4.0%).
Net debt as of April 30, 2025, was €261.1 million, with leverage ratio stable at 1.3–1.34x.
Cash absorption peaked at end of April due to seasonality, but full-year cash generation target of over €70 million reaffirmed.
Adjusted results exclude IFRS16 and non-recurring items.
Outlook and guidance
Sales have accelerated since May, showing mid-single-digit growth compared to 2024, with no risks seen to 2025 growth targets.
Gross margin expected to benefit from favorable FX, lower raw material costs, and improved supplier terms.
Full-year guidance excludes Goldenpoint; core business expected to meet consensus.
2026 profitability expected to benefit from cost reductions and favorable macroeconomic trends.
Latest events from OVS
- Q1 sales and margins rose, with strong brand momentum and a positive outlook for 2024.OVS
Q1 20253 Feb 2026 - Sales and margins rose in H1 2024, with strong September momentum and positive outlook.OVS
Q2 202520 Jan 2026 - Q3 2024 delivered double-digit sales and EBITDA growth, with robust outlook and share buybacks.OVS
Q3 202511 Jan 2026 - Sales up 6.2%, margins and cash flow improved, with higher dividend and buyback ahead.OVS
Q4 202523 Dec 2025 - Sales and EBITDA up, leverage improved, and outlook remains positive for year-end.OVS
Q3 202618 Dec 2025 - Record sales and profit growth in 1H 2025, with strong outlook and Goldenpoint boost.OVS
Q2 202616 Dec 2025